<DOC>
	<DOCNO>NCT01078142</DOCNO>
	<brief_summary>This multicenter , open label , single arm , phase I/II study . There placebo usage within trial . Phase I : Primary : To establish maximum tolerate dose addition Temsirolimus regimen Bendamustine Rituximab ( BERT ) patient relapse follicular lymphoma mantle cell lymphoma . Phase II : Primary : To evaluate ORR patient MCL FL treat establish BERT dose Secondary : To determine complete remission rate , progression free survival rate overall survival rate investigate safety tolerability BERT .</brief_summary>
	<brief_title>Temsirolimus , Bendamustine Rituximab Relapsed Follicular Lymphoma Mantle Cell Lymphoma</brief_title>
	<detailed_description>The first part study phase I study maximum tolerate dose combination Temsirolimus , Bendamustine Rituximab establish . In phase I part trial 3 patient include dose level . After inclusion 3 patient , patient receive least 2 complete cycle without DLT enrolment next cohort initiate . In case one DLT , 3 additional patient add specific dose level . If second DLT appear , last dose level without DLT consider standard dose phase II trial . If third dose level achieve without DLT , dose escalation . In phase II proportion trial , establishment maximum tolerate dose , efficacy combination regimens two different patient cohort evaluate . In one cohort , 30 patient relapse mantle cell lymphoma treat ; second cohort compose 30 patient relapse follicular lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically proven diagnosis follicular nonHodgkin 's lymphoma grade l , II IIIA mantle cell lymphoma ( include Cyclin D1 expression ) accord World Health Organization classification Documented relapse progression follow least one 3 antineoplastic treatment At least 1 measurable tumor mass ( &gt; 1.5 cm x &gt; 1.0 cm ) bone marrow infiltration Subjects 18 year old Status post . high dose therapy transplantation option available patient refuse aggressive treatment strategy Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Adequate bone marrow reserve : Platelets least 75000/µl , absolute neutrophil count least 1500/µl . In case extensive bone marrow infiltration lower platelet absolute neutrophil count , patient include phase I part trial . In phase II proportion trial patient may include platelet count equal 50000/µl discretion investigator , thrombocytopenia associate massive bone marrow infiltration . Adequate hepatic renal function Alanine aminotransferase &lt; 2.5 x upper limit normal ( ULN ) ; Aspartate aminotransferase &lt; 2.5 x ULN , Total bilirubin &lt; 1.5 x ULN Measured calculate creatinine clearance &gt; 50 mL/min Eastern Cooperative Oncology Group [ ECOG ] performance Status 02 Female subject must postmenopausal ( least 6 month ) , surgically sterile , abstinent , , sexually active , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) entry throughout study ; negative serum ßhCG pregnancy test screen Lymphoma MCL FL Active central nervous System lymphoma . Brain MRI require clinically indicated Pregnancy breast feed woman Severe concomitant disease ( e.g . uncontrolled arterial hypertension , heart failure ( NYHA IIIIV ) , uncontrolled diabetes mellitus , pulmonary fibrosis , uncontrolled hyperlipoproteinemia ) Active uncontrolled infection include HIVpositivity , active Hep B C Mental status preclude patient 's compliance Comedication strong CYP 3A4/5inhibitors inducer ( Appendix 22.7 ) Prior treatment Temsirolimus Known CD20 negativity Patients refractory Bendamustine prior treatment line , define relapse within 1 year initiation first cycle . Exception : termination treatment prior third schedule cycle reason toxicity . Status post allogeneic transplantation Peripheral neuropathy neuropathic pain Grade 2 bad Diagnosed treated malignancy NHL except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , DCIS breast , solid tumor curatively treat evidence disease &gt; 5 year Concurrent treatment another investigational agent . Concurrent participation nontreatment study exclude . Known intolerance sirolimus derivates , Bendamustine Rituximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>temsirolimus</keyword>
	<keyword>bendamustine</keyword>
	<keyword>rituximab</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
</DOC>